Sandra Wear

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 654 citations · Full text

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman et al. · Blood · 2012 · 254 citations · Full text

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Ravi Vij, David S. Siegel, Sundar Jagannath et al. · British Journal of Haematology · 2012 · 176 citations · Full text

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Paul G. Richardson, David S. Siegel, Rachid Baz et al. · Blood · 2012 · 161 citations · Full text

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Andrzej Jakubowiak, Kent A. Griffith, Donna Reece et al. · Blood · 2011 · 89 citations · Full text